MDR Compliance Cost and Timeline: A Realistic Budgeting Guide for Manufacturers

Short answer: The cost of EU MDR (Regulation (EU) 2017/745) compliance cannot be reduced to one number; it depends on device class, the maturity of your existing documentation, the testing required, and the clinical data need. As an indication: for a Class IIa device, compliance from scratch totals roughly €60,000–150,000; Class IIb is €120,000–350,000; Class III or devices needing a clinical investigation can start at €400,000 and run into the millions. The timeline is typically 12–24 months for Class IIa/IIb and 2–4 years for Class III. Annual surveillance and maintenance costs are added on top.

Method note: the ranges below are typical values observed in our consulting practice in the Türkiye and EU market as of 2026; they are not a published dataset and are not a substitute for a firm quote. For your own budget, obtain written quotes from notified bodies and test laboratories.

Key takeaways

• The two biggest items: clinical evidence (especially if a clinical investigation is required) and notified body fees.
• The hidden cost: internal RA/QA staff time and the timeline stretched by deficiency cycles.
• The recurring cost: annual QMS surveillance audits, PSUR/PMCF updates, and the authorised representative fee.
• The cost of non-compliance: total loss of EU market access — usually larger than the cost of compliance.

This article is part of the What is the EU MDR? pillar and complements The MDR compliance process: 8 steps.

---

Cost components and indicative ranges

Item	What it covers	Indicative range (€)
Gap analysis + planning	Assessing the existing file against the MDR, roadmap	3,000 – 12,000
QMS implementation / update	ISO 13485 + MDR procedures, training, documents, (optional) eQMS software	15,000 – 60,000
ISO 13485 certification (NB)	Initial certification audit	8,000 – 20,000
Biocompatibility (ISO 10993)	Material characterisation + required tests	10,000 – 80,000+
Electrical safety / EMC (IEC 60601)	Type testing for active devices	15,000 – 45,000
Software validation (IEC 62304/62366)	MDSW lifecycle, usability	10,000 – 60,000
Shelf life / stability, sterilisation validation	Accelerated + real time, ISO 11135/11137	8,000 – 40,000
Clinical evaluation (CER)	Literature appraisal, CER writing, PMCF plan	8,000 – 40,000
Clinical investigation (if required)	Protocol, ethics/authority approval, sites, monitoring, statistics	100,000 – 1,000,000+
Notified body conformity assessment	QMS + technical documentation/design review (initial)	IIa: 15,000–40,000 · IIb: 25,000–70,000 · III: 50,000–150,000+
Authorised representative (EC REP) + PRRC	EU legal representation, annual	3,000 – 15,000 / year
Internal staff time	RA/QA, engineering, project management (opportunity cost)	Usually 20–40% of total budget
Consulting	Comprehensive support or specific work packages	15,000 – 120,000

Rough total by class (from scratch, single device)

Class	Initial compliance total (€)	Typical timeline
Class I (not Is/Im/Ir)	8,000 – 30,000	3–8 months
Class I (Is/Im/Ir)	20,000 – 60,000	6–12 months
Class IIa	60,000 – 150,000	12–20 months
Class IIb	120,000 – 350,000	14–24 months
Class III	400,000 – several million	24–48 months

Note: grouping several variants of the same technical documentation family into one submission lowers the per-device cost.

Annual maintenance costs

• QMS surveillance audit (NB): €4,000 – 10,000 / year
• PSUR / PMCF updates: €3,000 – 20,000 / year (by class and data volume)
• Authorised representative fee: €3,000 – 15,000 / year
• EUDAMED / ÜTS registration maintenance, UDI updates: low but continuous
• Recertification (every 5 years) and significant-change reviews

Factors that drive the cost

1. Device class and contact — implantable and Class III devices are the most expensive.
2. Clinical data position — a manufacturer with its own data finishes far cheaper than one needing a clinical investigation.
3. Existing documentation maturity — a well-kept MDD file lowers gap analysis and cost.
4. Portfolio strategy — grouping variants, retiring low-volume SKUs.
5. Notified body choice and queue — scope match and responsiveness directly affect the timeline.
6. Internal capacity — an experienced RA/QA team reduces the consulting need.

How to keep the budget under control

• Do an early gap analysis to bring surprises forward.
• Optimise the testing strategy with literature and material characterisation; avoid unnecessary tests.
• Set the clinical strategy up front: is equivalence defensible, or is PMCF the route?
• Sign with a notified body early and get in the queue.
• Group variants into one technical file.
• Phase the budget: spread it by year; smooth testing and NB fees across cash flow.

Frequently asked questions

Is there a single price for a "CE certificate"? No. The notified body fee is only one part of the total; testing, clinical and QMS items are often larger.

Does consulting pay for itself? For teams doing the MDR process for the first time, it usually produces a net saving by reducing deficiency cycles and rework — but this depends on the device and the team.

Are there discounts or grants for SMEs? Some notified bodies and public support programmes (e.g. export/R&D incentives) may partly cover certain items; check current programmes.

The most effective way to shorten the timeline? Complete the clinical data and GSPR evidence early, and apply to a notified body early.

How MEGACERT helps

We build a device-specific cost–timeline model, optimise the testing and clinical strategy, and help you compare notified body quotes. Let us set a realistic budget range in a free 30-minute call. → Contact. What a consultant does: What does an MDR consultant do, and when do you need one? (cluster link)

---

Sources

1. Regulation (EU) 2017/745, Annexes IX–XI (conformity assessment) and Annex VII (notified body requirements). EUR-Lex.
2. MDCG 2022-14 — Commission/NB status reports on MDR and IVDR capacity and access.
3. Notified body public fee schedules (e.g. TÜV SÜD, BSI, TSE, UDEM, Szutest) — request a current quote from the body concerned.
4. Test laboratory quotations (biocompatibility, EMC, software) — project-specific.

Last updated: 30 August 2026. Figures are indicative and not a substitute for a firm quote.

---